Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study

Breast Cancer Research : BCR
Chi-Chen HongNorman F Boyd

Abstract

Breast cancer risk may be determined by various genetic, metabolic, and lifestyle factors that alter sex hormone metabolism. Cytochrome P450 1A2 (CYP1A2) is responsible for the metabolism of estrogens and many exogenous compounds, including caffeine. In a cross-sectional study of 146 premenopausal and 149 postmenopausal women, we examined the relationships between CYP1A2 activity and known or suspected risk factors for breast cancer. Blood levels of sex hormones, lipids, and growth factors were measured. In vivo CYP1A2 activity was assessed by measuring caffeine metabolites in urine. Stepwise and maximum R regression analyses were used to identify covariates related to CYP1A2 activity after adjustment for ethnicity. In both menopausal groups CYP1A2 activity was positively related to smoking and levels of sex hormone binding globulin. In premenopausal women, CYP1A2 activity was also positively related to insulin levels, caffeine intake, age, and plasma triglyceride levels, and negatively related with total cholesterol levels and body mass index. In postmenopausal women CYP1A2 activity was positively associated with insulin-like growth factor-1, and negatively associated with plasma triglyceride, high-density lipoprotein choleste...Continue Reading

References

Jan 1, 1992·European Journal of Clinical Pharmacology·J D LaneC M Kuhn
Mar 17, 1992·Biochemical Pharmacology·C R BarnettC Ioannides
Nov 1, 1991·Clinical Pharmacology and Therapeutics·W Kalow, B K Tang
Jun 1, 1991·Clinical Pharmacology and Therapeutics·B K TangW Kalow
Feb 1, 1990·American Journal of Obstetrics and Gynecology·J A BaronF Levi
Jan 1, 1990·Annals of the New York Academy of Sciences·J J Michnovicz, H L Bradlow
Nov 1, 1985·Journal of the National Cancer Institute·M S LangleyD C Anderson
Jan 1, 1974·Clinical Endocrinology·D C Anderson
May 1, 1993·Clinical Pharmacology and Therapeutics·W Kalow, B K Tang
Jan 1, 1996·Annual Review of Pharmacology and Toxicology·J D Yager, J G Liehr
Dec 7, 1995·European Journal of Pharmacology·A IrizarC Ioannides
Mar 13, 1998·Breast Cancer Research and Treatment·M E Del GiudiceP J Goodwin
Mar 27, 1998·European Journal of Clinical Pharmacology·D SchrenkM Eichelbaum
May 30, 1998·Journal of the National Cancer Institute·J S BrunetS A Narod
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S ColdC Rose
May 8, 1999·British Journal of Clinical Pharmacology·A NordmarkA Rane
Sep 3, 1999·Journal of Clinical Pharmacology·B G PollockK A Condifer
Nov 24, 1999·The Journal of Clinical Endocrinology and Metabolism·X XuM S Kurzer
Sep 21, 2000·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·S M Haffner
Oct 19, 2000·Journal of the National Cancer Institute·D WartenbergT Woodruff
Feb 22, 2001·Annual Review of Physiology·D M Stocco
Jul 4, 2001·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·J ManjerL Janzon
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pamela J GoodwinNicky Hood
Mar 22, 2002·Clinical Pharmacology and Therapeutics·Gesche JürgensHanne Rolighed Christensen
Apr 18, 2002·Journal of the National Cancer Institute·T KeyUNKNOWN Endogenous Hormones and Breast Cancer Collaborative Group
Oct 10, 2002·British Journal of Cancer·N F BoydS Minkin
May 9, 2003·EHP Toxicogenomics : Journal of the National Institute of Environmental Health Sciences·Andrew G SmithDaniel W Nebert

❮ Previous
Next ❯

Citations

Dec 10, 2015·Journal of Caffeine Research·Jennifer L TempleHarriet de Wit
Jan 14, 2005·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Nicola NapoliReina Armamento-Villareal
Jun 26, 2018·Cancer Causes & Control : CCC·Lusine YaghjyanRulla M Tamimi
Mar 1, 2019·Journal of Molecular Evolution·Miguel A FuertesCarlos Alonso
Jul 21, 2005·International Journal of Cancer. Journal International Du Cancer·André NkondjockSteven A Narod
Jan 10, 2012·European Biophysics Journal : EBJ·Yong-Xian ShaoHai-Bin Luo
May 18, 2019·Clinical Pharmacology and Therapeutics·Sophie GravelVeronique Michaud
May 7, 2020·Food & Function·Noelia Morales-PrietoNieves Abril
Oct 8, 2016·Nutrition & Metabolism·Emily UrryHans-Peter Landolt
Sep 10, 2020·International Journal of Molecular Sciences·Anna Helena MazurekDariusz Maciej Pisklak
Apr 30, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Ayari ImeneSaguem Saad
Jun 3, 2021·International Journal of Molecular Sciences·Lucy DarakjianVeronique Michaud
Jun 11, 2021·Journal of Medicinal Chemistry·Igor ShamovskyChristian Tyrchan
Jul 9, 2021·European Journal of Drug Metabolism and Pharmacokinetics·Sherif M ShoiebAyman O S El-Kadi

❮ Previous
Next ❯

Methods Mentioned

BETA
urine collection
hysterectomy
bilateral oophorectomy
blood draw

Software Mentioned

SAS

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

© 2022 Meta ULC. All rights reserved